Media
News and press releases
Welcome to our media section. Check out the latest news and press releases from Cinclus Pharma and don’t hesitate to contact us if you need more information.
Latest pressreleases
Latest News
Christer Ahlberg presented at Stora Aktiedagen in Stockholm
Christer Ahlberg participated in Aktiespararnas event Stora Aktiedagen again on November 28th, this time in Stockholm. He presented Cinclus Pharma and the positive topline data released for our phase II eGERD study LEED.
Kjell Andersson - CSO and founder with decades in gastroenterology
It all started with a summer job at Astra Zeneca. Today, Kjell is one of Sweden's most experienced drug developers in acid secretion inhibition and has played an important role....
Christer Ahlberg presents Cinclus Pharma at Stora Aktiedagen
Christer Ahlberg participated in Aktiespararnas event Stora Aktiedagen in Gothenburg on November 7th. He presented Cinclus Pharma and the positive topline data released for our Phase II eGERD study LEED last week.
Last Patient Out (LPO) from the Phase II study of linaprazan glurate
On September 1st, we had LPO – Last Patient Out, from the Phase II study of linaprazan glurate. The study includes a total of 228 patients.
Cinclus Pharma in media
New research advances for Linc-owned pharmaceutical company
2022-11-04[Swedish link] Cinclus Pharma har presenterat positiva resultat i en fas 2-studie kring en behandling av magsyrarelaterade besvär.
Cinclus Pharma raises a quarter of a billion SEK - EQT founder among investors
2022-05-20|Swedish link] Cinclus Pharma tar in nära en kvarts miljard kronor i en riktad emission inför bolagets stundande börsnotering. Riskkapitalfonden Eir...
Cinclus raises 240 million for Losec follow-up
2022-05-20[Swedish link] Cinclus Pharma tar in cirka 240 miljoner kronor i en nyemission. Målet: att ta fram en uppföljare till magsårsläkemedlen Losec och Nexium...
Telegram: Bengt Julanders Linc invests in Cinclus Pharma
2022-05-20[Swedish link] Forskningsbolaget Cinclus Pharma genomför en kapitalanskaffning där bolaget tar in cirka 240 miljoner ...
Telegram: Cinclus Pharma raises SEK 240 million
2022-05-20[Swedish link] Cinclus Pharma, ett biofarmaceutiskt företag, har rest cirka 240 miljoner kronor genom en riktad nyemission. Syftet är att anskaffa ...
